COPENHAGEN, Denmark, November 9, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, has filed an
Detection of neoantigen-specific T cells directly ex vivo indicates strong EVX-01-induced immune responsesData further underlines the strong predictive performance of Evaxion’s AI-Immunology™ platformThe new biomarker
The data further validate the potential of EVX-04 as an off-the-shelf therapeutic vaccine for acute myeloid leukemiaData will be presented in a poster session at the American Society of Hematology (ASH) Annual Meeting
New data from the phase 2 trial with EVX-01 to be presented in both an oral and poster session COPENHAGEN, Denmark, November 3, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company
This international award, honoring "the best of the best" in medical innovation, represents yet another important external recognition of AI-Immunology™ COPENHAGEN, Denmark, October 30, 2026 - Evaxion A/S
EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses Three-year data from the EVX-01 phase 2 trial in patients with advanced
Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 CongressData supplements unprecedented two-year data from the trial including a 75% Objective Response
New immune data from the phase 2 trial with EVX-01 to be presented both in an oral and poster presentationNew data follows from the three-year clinical update for EVX-01 to be provided at the European Society for
Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologiesThe unique capabilities of
COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and
EVX-05 is an off-the-shelf therapeutic glioblastoma (brain cancer) vaccine designed based on patient tumor samples. It targets novel conserved antigens identified using Evaxion’s AI-Immunology™ platformGlioblastoma is
COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business
Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune responseData will also offer insight into the vaccine’s effect
The new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation, further supporting the concept behind EVX-V1EVX-V1 is a next-generation, multi-component vaccine program
New preclinical data will guide antigen selection for a broadly protective cytomegalovirus vaccine candidatePoster presentation on July 12, 2026, at the International Herpesvirus Workshop 2026 taking place in Montreal,
